Laboratorios Farmaceuticos Rovi, S.A. (VIE:ROVI)

Market Cap	2.97B -1.3%
Revenue (ttm)	773.05M +3.2%
Net Income	185.18M +40.0%
EPS	3.62 +39.9%
Shares Out	n/a
PE Ratio	16.06
Forward PE	19.80
Dividend	0.78 (1.33%)
Ex-Dividend Date	Jul 13, 2026

Volume	n/a
Open	58.40
Previous Close	58.70
Day's Range	58.40 - 58.65
52-Week Range	53.15 - 86.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About VIE:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,470
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2025, VIE:ROVI's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 9, 2026

Data Sources Report a data error